Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Management of BK-virus in… - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Management of BK-virus infection - Swedish recommendations.

Artikel i vetenskaplig tidskrift
Författare Tina Dalianis
Britt-Marie Eriksson
Marie Felldin
Vanda Friman
Anna-Lena Hammarin
Maria Herthelius
Per Ljungman
Johan Mölne
Lars Wennberg
Lisa Swartling
Publicerad i Infectious diseases
Volym 51
Nummer/häfte 7
Sidor 479-84
ISSN 2374-4243
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin, avdelningen för patologi
Sidor 479-84
Språk en
Länkar dx.doi.org/10.1080/23744235.2019.15...
Ämnesord BK-virus nephropathy, transplantation, antiviral therapy
Ämneskategorier Infektionsmedicin


BK-virus (BKV) associated nephropathy (BKVAN) and BKV associated haemorrhagic cystitis (HC) are complications of BKV infection/reactivation in renal and allogeneic haematopoietic stem cell transplantation (HSCT) patients, respectively. The task of how to manage these diseases was given to the chair by the Swedish Reference Group for Antiviral Therapy (RAV). After individual contributions by members of the working group, consensus discussions were held in a meeting on 23 January 2018 arranged by RAV. Thereafter, the recommendations were published in Swedish on November 2018. The current translation to English has been approved by all co-authors. High BKV serum levels suggest an increased risk for BKVAN and potential graft failure. For detection of BKVAN, careful monitoring of BKV DNA levels in serum or plasma is recommended the first year after renal transplantation and when increased creatinine serum levels of unknown cause are observed. Notably, a renal biopsy is mandatory for diagnosis. To reduce the risk for progression of BKVAN, there is no specific treatment, and tailored individual decrease of immunosuppression is recommended. For BKV-HC, BKV monitoring is not recommended, since BK-viruria frequently occurs in HSCT patients and the predictive value of BKV in plasma/serum has not been determined. However, the risk for BKV-HC is higher for patients undergoing myeloablative conditioning, having an unrelated, HLA-mismatched, or a cord blood donor, and awareness of the increased risk and early intervention may benefit the patients. Also for BKV-HC, no specific therapy is available. Symptomatic treatment, e.g. forced diuresis and analgesics could be of use.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?